Ensartinib hydrochloride (Ensartinib) capsules efficacy and common uses

Ensartinib hydrochloride (Ensartinib) is a new oral ALK (anaplastic lymphoma kinase) inhibitor, mainly used to treat patients with ALK-positive non-small cell lung cancer (NSCLC), especially those with locally advanced or metastatic lesions. It is a second-generation ALK inhibitor that shows stronger targeting ability and broader anti-tumor activity against drug-resistant mutations or brain metastases that appear after treatment with first-generation drugs (such as crizotinib).

The main effect of ensartinib is to precisely inhibit the tumor growth pathway driven by abnormal ALK gene, thereby blocking the proliferation and metastasis of cancer cells. Studies have shown that in patients with ALK mutation-driven lung cancer, the use of ensartinib can significantly improve progression-free survival (PFS) and delay disease progression. Especially in patients with brain metastases, ensartinib can better penetrate the blood-brain barrier and exert anti-tumor effects in the central nervous system. It is an important alternative for patients with insufficient efficacy of crizotinib.

In terms of clinical application, ensartinib hydrochloride capsules are commonly used to treat non-small cell lung cancer patients with ALK fusion mutations confirmed by molecular testing, and are suitable for first-line treatment or second-line treatment after resistance to crizotinib. The medication is taken orally, once a day, and is relatively simple to use, which helps improve the patient's compliance with long-term treatment. It is also being studied to expand the treatment of other ALK-positive cancer types, such as certain types of lymphoma and neuroblastoma.
Overall, ensartinib, as a targeted precision drug, not only performs well in improving treatment efficiency, but also has unique advantages in controlling brain metastasis and prolonging survival time. With the advancement of more research, its position in the field of ALK-positive lung cancer treatment continues to be consolidated, and it is expected to provide long-term and safe treatment options for more patients. During the period of use, patients should conduct regular examinations as directed by the doctor to promptly evaluate the efficacy and adjust the treatment plan.
Reference: https://www.drugs.com/